Pfizer Inc. (PFE) - 5i Research

Pfizer Inc. (PFE $27.65)
- $27.65 P/E (TTM): 15.73X Cap: $154.08B
- View PFE Profile
- View Questions on PFE

{tplLang.businessdescription | toLang tLang}

{ profileData.description }

{tplLang.details | toLang tLang}

{tplLang.ceo | toLang tLang}

{profileData.profile.details.ceo}

{tplLang.employees | toLang tLang}

{profileData.profile.details.employees | numeraljs '0,0'}

{tplLang.issuetype | toLang tLang}

{profileData.profile.details.issuetype | asIssueType}

{tplLang.industryclassifications | toLang tLang}

{tplLang.sector | toLang tLang}

{profileData.profile.classification.sector}

{tplLang.industry | toLang tLang}

{profileData.profile.classification.industry}

{tplLang.toolname| toLang tLang}

There is no {tplLang.toolname| toLang tLang} currently available for {data.symbolstring}.

Regeneron Pharmaceuticals Inc. (REGN $781.67)
- $781.67 P/E (TTM): 18.97X Cap: $81.48B
- View REGN Profile
- View Questions on REGN
AbbVie Inc. (ABBV $232.08)
- $232.08 P/E (TTM): 175.18X Cap: $397.28B
- View ABBV Profile
- View Questions on ABBV
Merck & Company Inc. (MRK $123.82)
- $123.82 P/E (TTM): 16.37X Cap: $294.95B
- View MRK Profile
- View Questions on MRK
Pfizer Inc. (PFE $27.65)
- $27.65 P/E (TTM): 15.73X Cap: $154.08B
- View PFE Profile
- View Questions on PFE
Zoetis Inc. Class A (ZTS $131.10)
- $131.10 P/E (TTM): 20.9X Cap: $54.77B
- View ZTS Profile
- View Questions on ZTS

Q: Please rank these pharma stocks for a new buy and suggest any you may prefer. Thank you.

Read Answer Asked by Ken on February 18, 2026

Merck & Company Inc. (MRK $123.82)
- $123.82 P/E (TTM): 16.37X Cap: $294.95B
- View MRK Profile
- View Questions on MRK
Pfizer Inc. (PFE $27.65)
- $27.65 P/E (TTM): 15.73X Cap: $154.08B
- View PFE Profile
- View Questions on PFE

Q: Given the sector's relative under performance, I believe the timing is right to increase my portfolio weighting in the Healthcare Sector. I own MRK and PFE. As I started to research individual companies it became apparent my lack of expertise in the area and the pace of technological advance makes stock picking in this area challenging. As such I'm considering an ETF and am currently looking at RSPH. Do you agree with the timing and would you advise an ETF or another individual company? If the former, what do you think of RSPH and if the latter' what would recommend for global exposure to the sector

Thank-you

Any input appreciated,

Read Answer Asked by jeff on February 02, 2026

Pfizer Inc. (PFE $27.65)
- $27.65 P/E (TTM): 15.73X Cap: $154.08B
- View PFE Profile
- View Questions on PFE
Pfizer CDR (CAD Hedged) (PFE $12.46)
- $12.46 P/E (TTM): 18.9X Cap: $211.44B
- View PFE Profile
- View Questions on PFE

Q: With almost a 7% Dividend, is it a good choice? In TFSA or RRIF to avoid W/H Taxes?

Thanks Kindly!

Read Answer Asked by Austin on January 13, 2026